Thoracic metabolic tumor volume predicts survival in advanced lung adenocarcinoma: a PET/computed tomography-based cohort study
Our findings emphasize the prognostic value of thoracic MTV as a robust, independent biomarker for advanced-stage lung adenocarcinoma. Integrating PET/CT metrics with clinical and molecular data may improve staging accuracy and inform treatment decisions, particularly in settings where mutational status alone is insufficient.
Authors
- Elgin Özkan (ORCID: https://orcid.org/0000-0001-8543-0744)
- Elif Şen (ORCID: https://orcid.org/0000-0001-9656-131X)
- Ecenur Dursun (ORCID: https://orcid.org/0000-0002-0379-6484)
- Serpil Dızbay Sak (ORCID: https://orcid.org/0000-0003-3666-3095)
- Ahmet Melih Sahin (ORCID: https://orcid.org/0000-0001-6570-8294)
Institutions
- Ankara University (TR)
- Pulmonary Associates (US)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1097/mnm.0000000000001983
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00